Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, discusses the findings from an indirect comparison of brexucabtagene autoleucel (brexu-cel) versus standard of care (SOC) in relapsed/refractory (R/R) mantle cell lymphoma (MCL). This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.